HC Wainwright reaffirmed their buy rating on shares of AzurRx BioPharma (NASDAQ:AZRX) in a research note released on Friday morning. HC Wainwright currently has a $6.00 price target on the stock.

“Our price target is derived from a discounted cash flow-based asset value of $115M for MS1819, using a 15% discount rate and 2% terminal growth rate, with 40% probability of success.”,” the firm’s analyst wrote.

Separately, ValuEngine upgraded shares of AzurRx BioPharma from a sell rating to a hold rating in a research report on Wednesday, May 2nd.

NASDAQ AZRX opened at $2.39 on Friday. AzurRx BioPharma has a 52-week low of $2.20 and a 52-week high of $5.25.

Several institutional investors have recently modified their holdings of AZRX. Opaleye Management Inc. acquired a new stake in shares of AzurRx BioPharma during the 2nd quarter valued at about $417,000. Ardsley Advisory Partners boosted its position in shares of AzurRx BioPharma by 66.3% during the 2nd quarter. Ardsley Advisory Partners now owns 137,197 shares of the company’s stock valued at $440,000 after acquiring an additional 54,697 shares in the last quarter. Parsons Capital Management Inc. RI boosted its position in shares of AzurRx BioPharma by 20.3% during the 1st quarter. Parsons Capital Management Inc. RI now owns 329,515 shares of the company’s stock valued at $1,035,000 after acquiring an additional 55,540 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of AzurRx BioPharma during the 2nd quarter valued at about $1,782,000. Institutional investors and hedge funds own 8.62% of the company’s stock.

AzurRx BioPharma Company Profile

AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.

Featured Story: Asset Allocation and Your Retirement

Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.